Medical AI company VUNO announced on the 23rd that it will participate in the Alzheimer's Association International Conference (AAIC), the world's largest global conference in the field of Alzheimer's, and officially launch its AI-based brain quantification medical device, VUNO Med-DeepBrain, in the U.S. market. AAIC is regarded as the most prestigious conference in the field of Alzheimer's and will be held this year from the 28th to the 1st of next month in Philadelphia, USA.
VUNO Med-DeepBrain was certified by the U.S. Food and Drug Administration (FDA) in October last year. Based on deep learning, it analyzes brain magnetic resonance imaging (MRI), segments the brain into more than 100 regions, and provides quantitative information on the degree of atrophy in each region within one minute. This helps medical professionals diagnose dementia diseases caused by major degenerative brain disorders such as Alzheimer's disease, vascular dementia, and frontotemporal dementia. It is also explained that it can contribute to the early selection of patients who are highly likely to progress from mild cognitive impairment to dementia.
At this event, VUNO plans to officially introduce VUNO Med-DeepBrain to the U.S. market for the first time through an on-site booth exhibition. To rapidly expand in the local market, the company will focus on increasing contact points with key opinion leaders (KOLs) to build a sales network, while actively pursuing discussions on partnerships with companies that have demand for brain MRI quantification technology. Through Q&A sessions with on-site participants, the clinical excellence of the product, clinical application cases, and recent updates will also be shared.
In the research sessions, three research results related to Alzheimer's and dementia will be presented. These include ▲Verification of the accuracy of automatic brain volume segmentation in the entorhinal cortex region and its association with Alzheimer's disease ▲Research on the application method of automatic brain volume analysis for differential diagnosis between behavioral variant and language variant of frontotemporal dementia (FTD) ▲Study on the method of quantifying the severity of brain atrophy in the continuous progression of Alzheimer's disease.
Lee Yeha, CEO of VUNO, said, “With the increasing demand for early diagnosis of dementia, we are introducing VUNO Med-DeepBrain to the world's largest medical market for the first time. Having participated in AAIC for the second time following last year, we will strive to secure as many contacts with KOLs as possible and build a sales network to create an opportunity for gradual expansion of U.S. sales.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
